RAREUltragenyx Pharmaceutical Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−35% vs 200-day) and a crowded short (+16% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −35% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, a few days of normal trading to cover. Down 3.3% since the previous count, up from 14.2% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How RARE is trading
Ultragenyx Pharmaceutical Inc. is −45% over the past year while the S&P 500 is +18%: 63 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −35%
vs 200-day average · a clear downtrend
- RSI (14)
- 57
RSI (14) · neutral
- Below its 52-week high
- 58%
Below its 52-week high
Details›
- Last close2026-10-09
- $15.49
- 1 monthS&P 500 +2.7%
- +7.6%
- 1 yearS&P 500 +18%
- −45%
- 5 yearsS&P 500 +88%
- −84%
- vs 50-day average$19.87
- −22%
- 52-week high
- $36.54
- 52-week low
- $12.90
- Annualised volatility
- 67%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$61K
| Year | Return |
|---|---|
| 2026 (year to date) | −33% |
| 2025 | −45% |
| 2024 | −12% |
| 2023 | +3.2% |
| 2022 | −45% |
| 2021 | −39% |
| 2020 | +224% |
| 2019 | −1.8% |
| 2018 | −6.3% |
| 2017 | −34% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 7 of 10 | +3.8% |
| Feb | 10 | 5 of 10 | +5.1% |
| Mar | 10 | 3 of 10 | −8.4% |
| Apr | 10 | 4 of 10 | +4.7% |
| May | 10 | 3 of 10 | −2.7% |
| Jun | 10 | 8 of 10 | +9.6% |
| Jul | 11 | 4 of 11 | −2.4% |
| Aug | 11 | 6 of 11 | +2.3% |
| Sep | 11 | 2 of 11 | −9.0% |
| Oct | 11 | 3 of 11 | −4.6% |
| Nov | 10 | 6 of 10 | +5.3% |
| Dec | 10 | 5 of 10 | +0.42% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.